[rHU-EPO in cancer patients. Target or wider use?].
THE DEBATE: Although some believe that rHu-EPO should not be widely used in malignant affections, others think that because of the varied impact of these anaemia, its wider use should be recommended. FOR A TARGET USE: Various observations (influence of the degree of extension of the myelomas to the skeleton and response to specific treatment in the case of myeloma, whatever the haemoglobin concentration, degree of prevention of rHu-EPO chemo-induced anaemia) are in favour of its use in selected patients. FOR A WIDER USE: The benefits of treatment with rHu-EPO are not limited to the symptomatology of anaemia but extend to its potential complications in the most fragile patients. Other than the risks of infection, the heavy costs of transfusions must also be taken into account.
Solignac
Marie
M
D000741:Anemia, Aplastic / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D001803:Blood Transfusion / Q000191:economics; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D006452:Hemoglobinometry; D006801:Humans; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy / Q000191:economics; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000191:economics; D011379:Prognosis; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000097:blood / Q000188:drug therapy* / Q000191:economics
D011994:Recombinant Proteins; D004921:Erythropoietin